May 12, 2014
In response to the scandal related to Chiba University Hospital’s VART study of Novartis Pharma’s angiotensin receptor blocker Diovan (valsartan), the hospital has suspended the use of Novartis’s products on May 8. The suspension will be “for the time being,”...read more